Dianthus Therapeutics (NASDAQ:DNTH) Stock Rating Upgraded by Baird R W

Dianthus Therapeutics (NASDAQ:DNTH) was upgraded by stock analysts at Baird R W to a “strong-buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports.

Several other brokerages have also commented on DNTH. Raymond James increased their price objective on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a research report on Thursday, April 18th. Wedbush increased their price target on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. HC Wainwright began coverage on shares of Dianthus Therapeutics in a report on Thursday, May 16th. They issued a “buy” rating and a $40.00 price objective for the company. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a research report on Friday. They set an “outperform” rating and a $58.00 price target for the company. Finally, Cantor Fitzgerald initiated coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They set an “overweight” rating on the stock. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $45.00.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $28.97 on Friday. Dianthus Therapeutics has a 1 year low of $6.58 and a 1 year high of $33.77. The firm has a market cap of $850.27 million, a PE ratio of -4.97 and a beta of 1.89. The company has a 50 day simple moving average of $25.27 and a two-hundred day simple moving average of $23.99.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The firm had revenue of $0.87 million for the quarter, compared to the consensus estimate of $0.48 million. As a group, research analysts anticipate that Dianthus Therapeutics will post -2.18 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Octagon Capital Advisors LP lifted its position in shares of Dianthus Therapeutics by 15.4% in the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after purchasing an additional 74,000 shares during the period. Vestal Point Capital LP purchased a new position in shares of Dianthus Therapeutics in the 4th quarter valued at approximately $1,404,000. Citigroup Inc. bought a new stake in shares of Dianthus Therapeutics during the third quarter valued at approximately $53,000. Hussman Strategic Advisors Inc. purchased a new stake in Dianthus Therapeutics in the first quarter worth $630,000. Finally, Tower Research Capital LLC TRC bought a new position in Dianthus Therapeutics in the fourth quarter worth $25,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.